Evercore ISI raised the firm’s price target on Edwards Lifesciences to $91 from $89 and keeps an In Line rating on the shares in an earnings preview for the MedTech, Life Science Tools and Diagnostics group.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on EW:
- Edwards Lifesciences Announces Senior Financial Leadership Transition
- Edwards Lifesciences reports results from data analysis from PARTNER trials
- 3 Best Healthcare Stocks to Buy in June 2024, as per Analysts
- M&A News: BDX Snaps Up Edwards Life’s Critical Care Unit in $4.2B Deal
- Edwards Lifesciences Announces Major Divestiture and Deal Cautions
Questions or Comments about the article? Write to editor@tipranks.com